PIK3CA mutation

News alerts, weekly reports and conference planners

Entrez ID:

5290

Related biomarkers:

‹

›

PIK3CA mutation	Colorectal Cancer	PIK3CA mutation	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA mutation	HER2 Negative Breast Cancer	PIK3CA mutation	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	AN2025 Sensitive: B - Late Trials AN2025 Sensitive : B	AN2025 Sensitive: B - Late Trials AN2025 Sensitive : B
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA mutation	Triple Negative Breast Cancer	PIK3CA mutation	Triple Negative Breast Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B
PIK3CA mutation	Colorectal Cancer	PIK3CA mutation	Colorectal Cancer	panitumumab Resistant: B - Late Trials panitumumab Resistant : B	panitumumab Resistant: B - Late Trials panitumumab Resistant : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	neratinib Resistant: B - Late Trials neratinib Resistant : B	neratinib Resistant: B - Late Trials neratinib Resistant : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	lapatinib Resistant: B - Late Trials lapatinib Resistant : B	lapatinib Resistant: B - Late Trials lapatinib Resistant : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	trastuzumab Resistant: B - Late Trials trastuzumab Resistant : B	trastuzumab Resistant: B - Late Trials trastuzumab Resistant : B
PIK3CA mutation	Colorectal Cancer	PIK3CA mutation	Colorectal Cancer	atezolizumab + cobimetinib Sensitive: B - Late Trials atezolizumab + cobimetinib Sensitive : B	atezolizumab + cobimetinib Sensitive: B - Late Trials atezolizumab + cobimetinib Sensitive : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	everolimus Sensitive: B - Late Trials everolimus Sensitive : B	everolimus Sensitive: B - Late Trials everolimus Sensitive : B
PIK3CA mutation	Non Small Cell Lung Cancer	PIK3CA mutation	Non Small Cell Lung Cancer	erlotinib Resistant: B - Late Trials erlotinib Resistant : B	erlotinib Resistant: B - Late Trials erlotinib Resistant : B
PIK3CA mutation	Gastric Cancer	PIK3CA mutation	Gastric Cancer	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	trastuzumab + MEN1611 Sensitive: C2 – Inclusion Criteria trastuzumab + MEN1611 Sensitive : C2	trastuzumab + MEN1611 Sensitive: C2 – Inclusion Criteria trastuzumab + MEN1611 Sensitive : C2
PIK3CA mutation	Uterine Cancer	PIK3CA mutation	Uterine Cancer	copanlisib Sensitive: C2 – Inclusion Criteria copanlisib Sensitive : C2	copanlisib Sensitive: C2 – Inclusion Criteria copanlisib Sensitive : C2
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	MEN1611 Sensitive: C2 – Inclusion Criteria MEN1611 Sensitive : C2	MEN1611 Sensitive: C2 – Inclusion Criteria MEN1611 Sensitive : C2
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2
PIK3CA mutation	Ovarian Cancer	PIK3CA mutation	Ovarian Cancer	CYH33 Sensitive: C2 – Inclusion Criteria CYH33 Sensitive : C2	CYH33 Sensitive: C2 – Inclusion Criteria CYH33 Sensitive : C2
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	MEN1611 Sensitive: C2 – Inclusion Criteria MEN1611 Sensitive : C2	MEN1611 Sensitive: C2 – Inclusion Criteria MEN1611 Sensitive : C2
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	GDC-0032 Sensitive: C2 – Inclusion Criteria GDC-0032 Sensitive : C2	GDC-0032 Sensitive: C2 – Inclusion Criteria GDC-0032 Sensitive : C2
PIK3CA mutation	Gastric Cancer	PIK3CA mutation	Gastric Cancer	AZD5363 Sensitive: C2 – Inclusion Criteria AZD5363 Sensitive : C2	AZD5363 Sensitive: C2 – Inclusion Criteria AZD5363 Sensitive : C2
PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2
PIK3CA mutation	Hormone Receptor Positive Breast Cancer	PIK3CA mutation	Hormone Receptor Positive Breast Cancer	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2
PIK3CA mutation	Solid Tumor	PIK3CA mutation	Solid Tumor	copanlisib Sensitive: C2 – Inclusion Criteria copanlisib Sensitive : C2	copanlisib Sensitive: C2 – Inclusion Criteria copanlisib Sensitive : C2
PIK3CA mutation	Non Small Cell Lung Cancer	PIK3CA mutation	Non Small Cell Lung Cancer	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
PIK3CA mutation	Triple Negative Breast Cancer	PIK3CA mutation	Triple Negative Breast Cancer	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3
PIK3CA mutation	Urothelial Cancer	PIK3CA mutation	Urothelial Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
PIK3CA mutation	Non Small Cell Lung Cancer	PIK3CA mutation	Non Small Cell Lung Cancer	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	ribociclib Sensitive: C3 – Early Trials ribociclib Sensitive : C3	ribociclib Sensitive: C3 – Early Trials ribociclib Sensitive : C3
PIK3CA mutation	Hormone Receptor Positive Breast Cancer	PIK3CA mutation	Hormone Receptor Positive Breast Cancer	fulvestrant + anastrozole Sensitive: C3 – Early Trials fulvestrant + anastrozole Sensitive : C3	fulvestrant + anastrozole Sensitive: C3 – Early Trials fulvestrant + anastrozole Sensitive : C3
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	CDK6 inhibitor Resistant: C3 – Early Trials CDK6 inhibitor Resistant : C3	CDK6 inhibitor Resistant: C3 – Early Trials CDK6 inhibitor Resistant : C3

PIK3CA mutation

Associations